166 related articles for article (PubMed ID: 2644890)
41. The role of interleukin-2 in cancer immunotherapy.
Eberlein TJ; Schoof DD
Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
[TBL] [Abstract][Full Text] [Related]
42. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
43. Potential uses of interleukin 2 in cancer therapy.
Cheever MA; Thompson JA; Peace DJ; Greenberg PD
Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434
[TBL] [Abstract][Full Text] [Related]
44. IL-2/LAK cell treatment for advanced cancers with emphasis on a novel administration.
Auber ML; DeHaven JI; Raich PC; Rogers JS; Crowell EB; Romero P; Mahin EJ; Sosnowski JT; Lamm DL
W V Med J; 1991 Aug; 87(8):344-6. PubMed ID: 1949753
[TBL] [Abstract][Full Text] [Related]
45. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
46. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
Malkovska V; Sondel PM
J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
[TBL] [Abstract][Full Text] [Related]
47. [Interleukin-2 based immunotherapy of cancer].
Geertsen PF; Hermann GG; Claësson MH; Steven K; Zeuthen J; von der Maase H
Ugeskr Laeger; 1990 Nov; 152(47):3513-7. PubMed ID: 2256204
[TBL] [Abstract][Full Text] [Related]
48. Dermatologic changes associated with adoptive immunotherapy of cancer.
Gaspari AA
Semin Dermatol; 1991 Sep; 10(3):178-87. PubMed ID: 1931566
[TBL] [Abstract][Full Text] [Related]
49. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.
Bergstrom RW; Atkins MB; Mier JW; Palmer JP
J Clin Lab Immunol; 1990 Apr; 31(4):189-93. PubMed ID: 1967063
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
Richards JM
Blood Rev; 1989 Jun; 3(2):110-9. PubMed ID: 2673443
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-2 immunotherapy in children.
Chien CH; Hsieh KH
Pediatrics; 1990 Dec; 86(6):937-43. PubMed ID: 2174536
[TBL] [Abstract][Full Text] [Related]
52. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.
Grimm EA
Biochim Biophys Acta; 1986 Dec; 865(3):267-79. PubMed ID: 3539198
[TBL] [Abstract][Full Text] [Related]
53. [Recent trends in cancer treatment using cytokines].
Urushizaki I
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
[TBL] [Abstract][Full Text] [Related]
54. [Studies on the influence of interleukin 2 (IL-2) on antitumor effector mechanisms in patients with cervical cancer].
Yamamoto K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Dec; 38(12):2251-8. PubMed ID: 3492578
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
[TBL] [Abstract][Full Text] [Related]
56. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA; Fisher RI; Weiss GR; Margolin K; Aronson FR; Hawkins MJ; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):216-23. PubMed ID: 7834121
[TBL] [Abstract][Full Text] [Related]
57. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models.
Ottow RT; Steller EP; Sugarbaker PH; Wesley RA; Rosenberg SA
Cell Immunol; 1987 Feb; 104(2):366-76. PubMed ID: 3493081
[TBL] [Abstract][Full Text] [Related]
59. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
60. Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer.
Skibber JM; Lotze MT; Uppenkamp I; Ross W; Rosenberg SA
J Surg Res; 1987 Jun; 42(6):613-21. PubMed ID: 3295393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
